The components of the Wnt5a-ROR signaling pathway have been shown to overexpress in several hematological and non-hematological malignancies, including breast, colon, melanoma, lung, and pancreatic cancer (Diamanti et al., 2019; Enayati et al., 2019; Menck et al., 2021). Here, WNT5A is linked to hematologic disorder.